Ruxolitinib controls lymphoproliferation and Diabetes in a STAT3-GOF patientPEOPLE with diabetesCELL receptorsINSULIN derivativesTYPE 1 diabetesRUXOLITINIBJournal of Clinical Immunology -doi:10.1007/s10875-020-00864-wOliver WegehauptTina Muckenhaupt
STAT3 GOF MUTATION MIMICKING AUTOIMMUNE LYMPHOPROLIFERATION SYNDROME (ALPS)Neth, Olaf
Additionally, STAT3 GOF CD8 +T cells demonstrate decreased IL-2 production and proliferation. We identify increased expression of the ecto-enzyme, CD39, which has been reported on exhausted cells and hydrolyzes extracellular ATP, on CD8 +T cells from STAT3 GOF patients and in a mouse model of...
Interestingly, unlike STAT3 dominant negative variants, cytokine secretion by activated peripheral blood STAT3 GOF CD4+ T cells and frequencies of Treg cells were intact, suggesting CD4+ T cell dysregulation likely occurs at sites of disease rather than the periphery CONCLUSION. This study provides an...
The Treatment and Transplant Experience in STAT3 GOF DiseaseForbes, Lisa R
HEMOPHAGOCITIC LYMPHOHISTIOCYTOSIS (HLH) IN A PATIENT WITH A NOVEL STAT3GOF MUTATION.Forbes, Lisa R